IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.401
EU - Europa 3.759
AS - Asia 3.723
SA - Sud America 399
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 13.364
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.293
SG - Singapore 1.435
CN - Cina 1.113
IT - Italia 539
UA - Ucraina 531
IE - Irlanda 508
GB - Regno Unito 438
RU - Federazione Russa 398
TR - Turchia 369
SE - Svezia 368
VN - Vietnam 361
FR - Francia 339
BR - Brasile 331
DE - Germania 234
FI - Finlandia 141
IN - India 134
PL - Polonia 126
HK - Hong Kong 72
CA - Canada 54
MX - Messico 44
BD - Bangladesh 35
JP - Giappone 33
ZA - Sudafrica 31
AR - Argentina 30
SA - Arabia Saudita 28
CZ - Repubblica Ceca 27
BE - Belgio 23
ES - Italia 23
IQ - Iraq 21
KR - Corea 19
ID - Indonesia 16
AT - Austria 15
NL - Olanda 15
LT - Lituania 12
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
UZ - Uzbekistan 10
IR - Iran 9
MA - Marocco 9
CL - Cile 7
EC - Ecuador 7
AU - Australia 6
CO - Colombia 6
PH - Filippine 6
VE - Venezuela 6
BY - Bielorussia 5
EU - Europa 5
JO - Giordania 5
LY - Libia 5
MY - Malesia 5
AZ - Azerbaigian 4
DZ - Algeria 4
EG - Egitto 4
KE - Kenya 4
PS - Palestinian Territory 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
GR - Grecia 3
IL - Israele 3
JM - Giamaica 3
KZ - Kazakistan 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
UY - Uruguay 3
BN - Brunei Darussalam 2
CH - Svizzera 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
LB - Libano 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
GY - Guiana 1
HR - Croazia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SN - Senegal 1
TO - Tonga 1
TW - Taiwan 1
Totale 13.364
Salva come PNG Salva come JPEG
Città #
Singapore 1.069
Chandler 662
San Jose 651
Jacksonville 583
Dublin 499
Ashburn 400
Dallas 336
Southend 312
Beijing 283
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Los Angeles 140
Ho Chi Minh City 115
Wilmington 101
Kraków 98
Cambridge 96
Hanoi 89
Chieti 87
Tongling 84
Altamura 79
New York 78
Santa Clara 74
The Dalles 71
Ann Arbor 67
Council Bluffs 67
Hong Kong 67
Nanchang 64
Boardman 53
Munich 50
Buffalo 47
Moscow 44
Shenyang 42
São Paulo 39
Woodbridge 38
Redondo Beach 34
Hebei 29
Pescara 29
Tianjin 29
Changsha 28
Grevenbroich 27
Hefei 27
Helsinki 27
Orem 27
Warsaw 27
Denver 24
Jiaxing 24
Montreal 24
Chicago 23
Riyadh 23
Rome 23
Tokyo 23
Washington 23
Brno 22
Seattle 22
Atlanta 21
Kocaeli 21
Brussels 20
Johannesburg 20
Kunming 20
Camerino 19
Hangzhou 19
Houston 19
Brooklyn 18
Phoenix 18
Seoul 18
Shanghai 18
Mexico City 17
Orange 17
St Louis 17
Norwalk 16
Spoltore 16
Da Nang 15
Manchester 15
Nuremberg 15
Poplar 15
Lappeenranta 14
Stockholm 14
Toronto 14
Boston 13
Chennai 13
Jinan 13
Mumbai 13
Ankara 12
Belo Horizonte 12
Düsseldorf 12
Haiphong 12
Frankfurt am Main 11
Guangzhou 11
Leawood 11
Lanzhou 10
London 10
Amsterdam 9
Dong Ket 9
Hải Dương 9
Rio de Janeiro 9
Augusta 8
Charlotte 8
Montesilvano 8
Totale 8.356
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 237
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 184
Antithrombotic Agents and Cancer 182
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 162
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 160
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 160
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 156
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 154
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 153
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 150
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 150
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 148
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 145
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 143
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 142
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 142
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 139
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 137
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 136
New insights into COX-2 biology and inhibition. 132
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 132
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 128
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 128
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 128
Oxidative stress and platelet activation in essential hyperytension 127
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 127
Platelet activation in patients with colorectal cancer. 126
Clinical pharmacology of selective COX-2 inhibitors. 126
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 124
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 124
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 123
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 123
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 121
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 121
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 121
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 120
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 120
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 120
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 120
Gut microbiota, host gene expression, and aging. 120
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 119
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 118
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 118
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 118
Risk management profile of etoricoxib: An example of personalized medicine 118
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 117
Clinical pharmacology of novel selective COX-2 inhibitors. 117
Determinants of platelet activation in human essential hypertension. 117
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 116
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 116
Mechanistic and pharmacological issues of aspirin as an anticancer agent 116
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 116
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 115
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 115
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 115
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 115
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 113
NSAIDs and cardiovascular disease. 113
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 113
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 112
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 112
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 112
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 111
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 111
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 111
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 110
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 110
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 109
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 108
Pharmacodynamic of cyclooxygenase inhibitors in humans. 108
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 107
Clinical pharmacology of etoricoxib. 106
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 105
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 105
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 103
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 103
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 102
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 102
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 102
P2Y12 Receptors in Tumorigenesis and Metastasis 99
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 96
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 96
Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro 96
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 95
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 95
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 94
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 94
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 93
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 92
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 92
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 92
Human pharmacology of naproxen sodium. 92
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 91
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 91
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A2 receptor 90
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 90
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. 90
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 90
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 89
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 89
Totale 11.891
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.025
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021224 0 0 0 0 0 0 0 0 0 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/20264.790 443 250 526 672 471 307 829 328 558 406 0 0
Totale 13.832